目的探讨吉西他滨+顺铂(GP)方案和吉西他滨+紫杉醇(GT)方案治疗复发转移性乳腺癌的临床疗效和安全性。方法选择86例复发转移的乳腺癌女性患者,随机分为GP组(42例)和GT组(44例)。GP组患者在第1天和第8天接受吉西他滨(1000 mg/m2)治疗,在第1天至第3天接受顺铂(25 mg/m2)治疗。GT组患者在第1天接受紫杉醇(135 mg/m2)治疗,在第1天和第8天接受吉西他滨(850 mg/m2)治疗。比较两组患者的近期疗效和不良反应。结果 GP组和GT组患者的中位生存时间分别为12.1个月和12.5个月,治疗有效率分别为42.9%和40.9%,疾病控制率分别为66.7%和65.9%,两组差异无统计学意义(P>0.05)。GP组患者的Ⅲ~Ⅳ度白细胞减少、血小板减少、贫血和恶心呕吐的发生率分别为11.9%、7.1%、14.3%和16.7%;GT组患者的Ⅲ~Ⅳ度白细胞减少、血小板减少、贫血和恶心呕吐的发生率分别为13.6%、4.5%、11.4%和15.9%,两组比较差异无统计学意义(P>0.05)。GT组患者的脱发发生率(22.7%)显著高于GP组(7.1%),差异有统计学意义(P<0.05)。结论 GP方案与GT方案治疗复发转移性乳腺癌临床疗效相当,不良反应可耐受。 Objective To investigate the clinical efficacy and safety of gemcitabine + cisplatin (GP) regimen and gemcitabine + paclitaxel (GT) regimen in the treatment of recurrent breast cancer. Methods Totally 86 female patients with breast cancer who had recurred and metastasized were randomly divided into GP group (42 cases) and GT group (44 cases). Patients in the GP group received gemcitabine (1000 mg / m2) on days 1 and 8 and cisplatin (25 mg / m2) on days 1 to 3. Patients in the GT group received paclitaxel (135 mg / m2) on day 1 and gemcitabine (850 mg / m2) on days 1 and 8. The short-term efficacy and adverse reactions of the two groups were compared. Results The median survival time of patients in GP group and GT group were 12.1 months and 12.5 months, respectively. The effective rates were 42.9% and 40.9%, and the disease control rates were 66.7% and 65.9% respectively. There was no significant difference between the two groups Significance (P> 0.05). The incidences of grade Ⅲ ~ Ⅳ leukopenia, thrombocytopenia, anemia and nausea and vomiting in GP group were 11.9%, 7.1%, 14.3% and 16.7%, respectively. The levels of Ⅲ ~ Ⅳ leukopenia, thrombocytopenia, anemia And nausea and vomiting were 13.6%, 4.5%, 11.4% and 15.9% respectively. There was no significant difference between the two groups (P> 0.05). The incidence of alopecia (22.7%) in GT group was significantly higher than that in GP group (7.1%), the difference was statistically significant (P <0.05). Conclusion GP regimen has the same clinical effect as GT regimen in the treatment of recurrent metastatic breast cancer, and adverse reactions are tolerable.